Regeneron Pharmaceuticals, Inc.
Corporate Headquarters
777 Old Saw Mill River Road
Tarrytown
New York
10591
United States
Tel: 914-847-7000
Website: https://www.regeneron.com/
About Regeneron Pharmaceuticals, Inc.
Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye disease, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, infectious diseases, pain and rare diseases.
Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune® which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.
Stock Symbol: REGN
Stock Exchange: NASDAQ
Every day, we use our homegrown technologies to discover, develop, research and deliver new medicines that help people with serious diseases. Watch to see what drives us.
Learn more about how our team produces the highest-quality treatments for patients at https://www.regeneron.com/.
1400 articles about Regeneron Pharmaceuticals, Inc.
-
According to a recent BioSpace survey, 93% of respondents are open to a new job for the right opportunity. Are you one of the 93%? If so, keep your eyes open for those opportunities and don't stop looking. You never know what may come your way!
-
Whenever drug companies come under criticism for the cost of their drugs, one of the defenses touted is that only about one in 10 drugs make it to market. As a broad figure, that’s probably about right, although at least one report ranks it higher, while another provides a bit more nuance.
-
Calixar signs exclusive licensing agreement with Regeneron on undisclosed therapeutic target
4/29/2019
Calixar SAS announces that it has entered into an exclusive licensing agreement with Regeneron Pharmaceuticals, Inc.
-
Regeneron Announces Upcoming Investor Conference Presentations - April 29, 2019
4/29/2019
Regeneron Pharmaceuticals, Inc. will webcast management presentations
-
This week has a number of approvals expected by the U.S. Food and Drug Administration. Let’s take a look.
-
Calixar is providing Regeneron exclusive rights to its technology and expertise. Regeneron plans to work on developing antibodies against an undisclosed target in several different therapeutic areas.
-
FDA Approves Praluent® (alirocumab) to Prevent Heart Attack, Stroke and Unstable Angina Requiring Hospitalization
4/27/2019
Praluent is the first PCSK9 inhibitor that has shown a meaningful reduction in death from any cause
-
CHMP Issues Positive Opinion for Libtayo® (cemiplimab) in Advanced Cutaneous Squamous Cell Carcinoma
4/26/2019
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the marketing authorization of Libtayo® (cemiplimab).
-
The study, which uses data gathered from Great Places to Work, points to the company’s openness from its leadership and the treatment of its employees as the primary reason it took the top spot.
-
Regeneron to Report First Quarter 2019 Financial and Operating Results and Host Conference Call and Webcast on May 7, 2019
4/8/2019
Regeneron Pharmaceuticals, Inc. announced that it will report its first quarter 2019 financial and operating results on Tuesday, May 7, 2019, before the U.S. financial markets open.
-
Regeneron and Alnylam Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases
4/8/2019
Companies to also jointly advance select number of preclinical disease programs with targets expressed in the liver and treatments for C5 complement-mediated diseases
-
Alnylam and Regeneron Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases
4/8/2019
Companies to Also Jointly Advance Select Number of Preclinical Disease Programs with Targets Expressed in the Liver and Treatments for C5 Complement-Mediated Diseases
-
Under the terms of the agreement, Regeneron is paying $400 million upfront to Alnylam and acquiring another $400 million in equity at a price per share of $90, or 4.44 million common shares.
-
Praluent® (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease
3/15/2019
Approval is based on ODYSSEY OUTCOMES trial of 18,924 patients who recently suffered an acute coronary syndrome such as a heart attack
-
Teen Scientists Win $1.8 Million at Regeneron Science Talent Search 2019 with Innovative Ideas on Exoplanets, HIV and a Classic Math Problem
3/13/2019
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science & the Public announced that Ana Humphrey, 18, of Alexandria, Virginia, won the top award in the Regeneron Science Talent Search, the nation's oldest and most prestigious science and math competition for high school seniors.
-
Regeneron and Sanofi to Present New Praluent® (alirocumab) Data at ACC.19
3/13/2019
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that four new sub-analyses from the Praluent® (alirocumab) ODYSSEY OUTCOMES cardiovascular (CV) outcomes trial will be presented at the American College of Cardiology's 68th Annual Scientific Session (ACC.19), held March 16-18, in New Orleans, LA.
-
FDA Approves Dupixent® (dupilumab) for Moderate-to-severe Atopic Dermatitis in Adolescents - March 12, 2019
3/12/2019
Only therapy that targets the IL-4/IL-13 pathway, a key driver of the allergic or type 2 inflammation that underlies atopic dermatitis In a Phase 3 trial, Dupixent significantly reduced the extent and severity of disease and itching, and helped adolescents achieve clearer skin [12-March-2019] TARRYTOWN, N.Y. and CAMBRIDGE, Mass. , March 12, 2019 /PRNewswir
-
FDA Green-Lights Two Therapies, While Late-Stage Successes Set Stage for Potential Approvals
3/12/2019
The U.S. Food and Drug Administration has been busy approving new treatments for various diseases. Two days into the new week and the regulatory agency has green lit two therapeutics, while other companies are planning to file for potential approval. -
With Cowen & Company’s 39th Annual Health Care Conference going on in Boston this week, a lot of stories in the biopharma industry are coming out. Here are a few highlights.
-
FDA Approves Dupixent® (dupilumab) for Moderate-to-severe Atopic Dermatitis in Adolescents
3/11/2019
Only therapy that targets the IL-4/IL-13 pathway, a key driver of the allergic or type 2 inflammation that underlies atopic dermatitis